Sandoz Group
Sandoz Group AG is a Swiss global pharmaceutical company specializing in generic prescription medicines and biosimilars, operating independently following its spinoff from Novartis. The company researches, manufactures, and markets generic oral solids, anti-infectives, complex generics, and biosimilar biologic therapeutics across oncology, immunology, and endocrinology, including Omnitrope and Hyrimoz. Main revenue drivers comprise global commercial sales of generic prescription pharmaceuticals, biosimilar biologics, and active pharmaceutical ingredients (APIs). Sandoz serves hospital networks, prescription pharmacies, healthcare authorities, and patients across Europe, North America, Asia, and Latin America. The enterprise holds a world-dominant market position as a premier global leader in generic pharmaceuticals and biosimilar therapies. Headquartered in Basel, Switzerland, Sandoz Group AG is listed on the SIX Swiss Exchange.
58 of the funds FundTelligence covers report a position in Sandoz Group.
- Legal name
- SANDOZ GROUP AG
- Sector
- Health Care
- Country
- Switzerland
- Funds holding it
- 58
Funds holding Sandoz Group
- Fidelity Switzerland Fund — Fidelity · 5.0 % (largest positions only, October 2026)
- UBS Sustainable Health Transformation Equity Fund — UBS · 4.4 % (largest positions only, September 2026)
- Fondita Global Megatrends — Fondita · 3.63 % (largest positions only, October 2026)
- Danske Invest Europe High Dividend — Danske Invest · 3.05 % (full portfolio disclosed, September 2026)
- Baillie Gifford Worldwide Positive Change Fund — Baillie Gifford · 2.93 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI Europe Health Care Sector UCITS ETF — BlackRock · 2.17 % (full portfolio disclosed, October 2026)
- Schroder ISF European Sustainable Equity — Schroders · 2.1 % (full portfolio disclosed, June 2026)
- Handelsbanken Infrastruktur och Beredskap — Handelsbanken · 1.99 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 58 funds holding it.